Oberland Capital
Oberland Capital provides innovative financing solutions to companies .
Business Model:
Revenue: $3.5M
Employees: 11-50
Rankings
Detailed Oberland Capital Information
Geographic Data
Address: 1700 Broadway
City: New York
State: NY
Zip: 10019
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
4,409,444Website Global Rank
2,720Website Monthly Traffic
Twitter Followers
Description
Oberland Capital provides innovative financing solutions to companies and royalty holders in the healthcare industry. We specialize in flexible investment structures customized to meet the specific capital requirements and strategic objectives of transaction partners globally. Our broad suite of financing solutions includes monetization of royalty streams, acquisition of future product revenues, creation of project-based financing structures, and investment in debt and equity securities. With a combination of deep industry knowledge and extensive structured finance experience, the Oberland Capital team has a history of creating value for our transaction partners.
Contact Phone:
+12122575850
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2019 | NorthStar Medical Radioisotopes | Venture Round | 0 |
| 4/2021 | Esperion | Post-IPO Equity | 50M |
| 12/2020 | Mirum Pharmaceuticals | Post-IPO Equity | 0 |
| 10/2017 | Impact Biomedicines | Debt Financing | 0 |
| 1/2023 | Helsinn Healthcare | Venture Round | - |
| 12/2021 | Zealand Pharma | Post-IPO Debt | 0 |
| 10/2021 | Centessa Pharmaceuticals | Post-IPO Debt | 0 |
| 10/2020 | Primmune Therapeutics | Series A | 0 |
| 6/2017 | Melinta Therapeutics | Post-IPO Equity | 0 |
| 12/2021 | Zealand Pharma | Post-IPO Debt | 0 |
| 10/2021 | Centessa Pharmaceuticals | Post-IPO Debt | 0 |
| 4/2021 | Esperion | Post-IPO Equity | 0 |
| 12/2020 | Mirum Pharmaceuticals | Post-IPO Equity | 0 |
| 10/2020 | Primmune Therapeutics | Series A | 0 |
| 4/2019 | NorthStar Medical Radioisotopes | Venture Round | 0 |
| 10/2017 | Impact Biomedicines | Debt Financing | 0 |
| 6/2017 | Melinta Therapeutics | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
